drugset / Trial / NCT01038843

Efficacy Study of VA106483 in Males With Nocturia.

NCT01038843 ↗

Phase 2 Completed 152 enrolled Vantia Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

To investigate the effect of VA106483 on nocturia related clinical outcomes compared to placebo.

Timeline

Start
2009-12
Primary completion
2010-07
Completion
2010-08

Drugs

EvaluationDrugModalityDoseRoute
Subject VA106483 Small molecule 1 mg Oral
Subject VA106483 Small molecule 2 mg Oral
Subject VA106483 Small molecule 4 mg Oral

Indications